Professor Stephen Mahler
|Professor Stephen Mahler|
BSc (Hons) Syd, PhD UQ
Affiliate Group Leader
Telephone: +61 7 3365 4172 or +61 7 3346 3175 Email: firstname.lastname@example.org
Research: Research and development of biologic medicines
Professor Stephen Mahler has made significant contributions to biopharmaceutical research and development and has been associated with translational research outcomes including development of monoclonal antibody biologics and antibody-targeted nanomedicines. He has secured more than $15 million in competitive research grants and industry funding during the past four years for projects principally associated with biologics discovery, recombinant protein production and development of targeted drug delivery systems. Professor Mahler has a track record of engagement with industry and is Director of the ARC Training Centre for Biopharmaceutical Innovation, partnering with CSL Ltd, the Australian Red Cross Blood Service, Patheon Biologics and GE Healthcare. He has collaborations with and consults for a wide range of biotechnology companies and industry stake holders both nationally and internationally.
Professor Mahler has delivered short courses in biologics nationally and internationally to big pharma, biotechnology companies, regulatory agencies and universities, including Pfizer Australia; the National Pharmaceutical Control Bureau, Malaysia; and at the National Forum for Biosimilars, Brazil. He has consulted for a wide range of biotechnology companies both nationally and internationally including Pfizer and Abbott. He also has academic collaborations with University of Cambridge United Kingdom and Nanyang Technological University, Singapore in the areas of Antibody Engineering and Targeted Drug Delivery, respectively.
Memberships, patents and funding
Professor Mahler has been a member of the editorial board of the Journal of Chemical Technology and Biotechnology since 2004; and an OzReader for the Australian Research Council since 2003, reviewing ARC Discovery, Linkage, Australian Federation Fellowship, Australian Future Fellowships and ARC Centre applications. Prior to joining the AIBN, Professor Mahler was co-director of the Bioengineering Centre at the University of NSW, and secured $2 million in National Collaborative Research Infrastructure Strategy (NCRIS) funding for establishing the Recombinant Products NCRIS node at UNSW. Since 2007, Professor Mahler has been interacting with biotechnology companies and has secured research funding from industry sources. Two provisional patent applications are now in the process of being submitted.
Awards and plenaries
- Molecular medicine conference Asia, May 2013 (Click here for details)
- Biopharma Asia Conference, March 2013 (Click here for details)
Key publications for past five years
Taylor K, Howard CB, Jones ML, Sedliarou I, MacDiarmid J, Brahmbhatt H, Munro TP and Mahler SM. (2015) Nanocell targeting using engineered bispecific antibodies. mAbs. 7, 53-65.
Goodall SF, Howard CB, Jones ML, Trent Munro TP, Zhongfan Zhi Z, Montiero M and Mahler SM. (2014) An EGFR targeting immunomicelle nanoparticle self-assembled with a thermoresponsive polymer. J. Chem. Technol. and Biotechnol. DOI: 10.1002/jctb.4509.
Leow H, Jones MJ, Cheng Q, Mahler SM and McCarthy J (2014) Production and characterization of specific monoclonal antibodies binding the Plasmodium falciparum diagnostic biomarker, histidine-rich protein II Malaria Journal 13, 277-287.
Goodall SF, Jones ML and Mahler SM. (2014) Monoclonal antibody-targeted polymeric nanoparticles for cancer therapy – future prospects. J. Chem. Technol. and Biotechnol. DOI 10.1002/jctb.4555
Munro TP, Mahler SM, Huang EP, Chin DY and Gray PP (2012) Bridging the gap: development of preclinical mAb candidates.Mabs 3, 440-452.
Pile KD, Graham GG, Mahler SM, Day RO. (2011) Disease-modifying antirheumatic drugs. In Principles of immunopharmacology (third ed.). Nijkamp FP, Parnham MJ (Eds.), (pp. 585-619) Basel, Switzerland: Springer.
Munro TP, Mahler SM, Huang EP, Chin DY, Gray PP. (2011) Bridging the gap: Facilities and technologies for development of early stage therapeutic mAb candidates. mAbs 3(5), 440-452.
Falconer RJ, Jackson-Matthews D, Mahler SM. (2011) Analytical strategies for assessing comparability of biosimilars. J Chem Technol and Biotechnol 86(7), 915-922.
|Professor Stephen Mahler section|